The FLEX Study demonstrates the prediction of chemotherapy benefit by MammaPrint® in patients with HR+HER2- early-stage breast cancer
Brufsky et al., JNCICS 2025. FLEX Study Real World Evidence prospective, propensity score matched study (n = 1002)
STUDY FINDINGS
- Minimal CT benefit was observed for Low and UltraLow Risk, while High 2 tumors observed a CT benefit of up to 14.2% compared to ET alone
- Consistent with findings from MINDACT, patients with MammaPrint indices within Low and UltraLow Risk ranges did not derive significant CT benefit
- CT benefit is not predicted by higher tumor grade after adjusting for MPI (MammaPrint Index) and clinical factors
Discuss the data with your local Agendia MOS & MSL
Request Data Review / Additional Data:
